In a crucial step towards understanding the mechanisms involved in cardiovascular disease and certain cancers, a Canadian led research team has succeeded in a world first: they've found the molecular ...

The PCSK9 inhibitor evolocumab (Repatha) got the FDA's blessing for cardiovascular protection, with or without a history of cardiovascular disease (CVD). Evolocumab is now indicated for the wider pool ...

Panelists discuss how PCSK9 inhibitors remain underused due to access, cost, and adherence barriers.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A once-daily oral PCSK9 inhibitor reduced LDL in ...

A new study suggests that the cholesterol-regulating protein PCSK9 may serve as a sensitive early biomarker for autoimmune ...

Please provide your email address to receive an email when new articles are posted on . An oral PCSK9 inhibitor lowered LDL cholesterol by up to 60% and improved other lipid parameters at 24 weeks.

Researchers from Mass General Brigham have unveiled the results of a large clinical trial that found that adding the drug evolocumab to patients' treatment significantly reduced the risk of major ...

Chronic kidney disease is a growing problem globally. A new study from Aarhus University shows that a protein known for treating heart diseases also affects a mechanism in the kidney that reabsorbs ...

PCSK9 inhibitors may have a role in dampening vascular inflammation to improve outcomes in severe COVID-19, a pilot study suggested. Among people with severe COVID-19 with respiratory failure and ...